1,2 Globally, there were an estimated 9.27 million new cases of TB in 2007. Most of these cases were in Asia (55%) and Africa (31%). Sadly, three Vincristine mw Asian countries topped the list, namely India (2.0 million), China (1.3 million) and Indonesia (0.53 million).1 Each year approximately 2 million people die from TB worldwide. A large proportion of deaths occur in the low-income countries of Asia and Africa.1,3 Unfortunately, women in these countries are most profoundly affected by TB, which is the third leading cause of death among women of reproductive age.4 As TB mostly occurs in young women,

many infected women are diagnosed having the disease during pregnancy, while others become pregnant during TB medication; and more importantly, a proportion remains undiagnosed and suffers worse maternal and perinatal consequences.5–17 A recent postmortem analysis of maternal deaths highlights that infection, including TB, is an important contributor to maternal death in India.17 Current literature on the prevalence of TB among pregnant women in developing countries like India is not available. Only a few studies, mostly from the large urban teaching hospitals in India, reported effects of TB during pregnancy.7–10 Considering the current incidence of TB among women of reproductive age (around 100 cases per 100 000 population) and

a total of 26 million births annually, our conservative estimate suggests that approximately Selumetinib mouse 20 000–40 000 women in India are likely to have active TB during pregnancy each year.18,19 Therefore, not only is there a knowledge gap, but also the true impact of this problem on the community is not known. Several descriptive studies, both old and new, often underestimated the maternal and perinatal complications of TB.9,14,20,21 Therefore, there is a sense of complacency among obstetricians regarding the benign course of both disease and pregnancy among these women suffering from TB. However, several recent reports from diverse

countries have tempered this false notion, and suggested that TB remains a potential danger for mother, fetus and newborn.7–13,21,22 Furthermore, resurgence of TB in immunocompromised mothers with www.selleck.co.jp/products/lonafarnib-sch66336.html HIV infection, and multidrug-resistant TB and extreme-drug-resistant TB have added new dimensions to an already complex issue.23,24 In this review, we plan to assemble current evidence regarding implications and management of maternal TB, especially in the context of South Asian countries. This is a non-systematic review, which deals with maternal and perinatal outcomes among pregnant women who suffered from TB during pregnancy or immediately prior to pregnancy or during the post-partum period. For this review, we carried out an electronic search supplemented by a manual search.